World Effectiveness and Safety of Upadacitinib in Crohn’s Disease: A Multi-Centre Study," published in the March 2025 issue ...

US biotech Incyte (Nasdaq: INCY) has reported positive results from two Phase III trials of povorcitinib, an oral JAK1 ...

Incyte’s quest for its next big thing ended in disappointment—and a stock tumble—this past week. Unfortunately, the problems ...

The two simultaneous Incyte trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.

Incyte has delivered a pair of pivotal wins for an oral JAK inhibitor in an inflammatory skin condition. But with the placebo ...

On Monday, Incyte Corporation (NASDAQ:INCY) released topline results from its pivotal Phase 3 STOP-HS clinical trial program ...

A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...

Shares of Incyte INCY were down 8.62% on Monday after the announcement of data from two late-stage studies on an oral ...

Findings on golidocitinib for patients with non-small cell lung cancer whose disease has progressed on anti-PD-1 therapy will ...

Incyte (INCY) announced topline results from its Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib, an ...

Shares of Incyte INCY were down 8.62% on Monday after the announcement of data from two late-stage studies on an oral small-molecule JAK1 inhibitor, povorcitinib, for the treatment of hidradenitis ...